Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bifidobacterium-derived extracellular vesicles
- Development stage
- Preclinical
- Lead developer
- Jinzhou Medical University
- Modality
- Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Intravenous (preclinical Studies)
01
Overview
Bifidobacterium-derived extracellular vesicles (EVs) are nanoscale membrane-bound particles secreted by Bifidobacterium species, particularly Bifidobacterium longum. These EVs contain diverse bioactive molecules such as proteins and nucleic acids that can modulate host cellular functions. Mechanistically, they have been shown to protect hepatocytes against fibrosis, apoptosis, and oxidative damage by modulating the TGF-β1/Smad signaling pathway in preclinical models of liver disease. Additionally, these EVs stimulate the innate immune system through the production of inflammatory cytokines (TNF-α and IL-6) from immune cells like macrophages and dendritic cells via clathrin-mediated endocytosis and macropinocytosis. They are being explored as novel nanomaterials for immunotherapy or adjuvant therapy due to their ability to activate host immune responses[1][2].
- Other names
- Bifidobacterium longum-derived extracellular vesiclesB.longum-EVprobiotic-derived EVs
02
Targets
TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on bifidobacterium-derived extracellular vesicles.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bifidobacterium-derived extracellular vesicles.